Pfizer Inc. (NYSE:PFE) Stake Lifted by Garland Capital Management Inc.
Garland Capital Management Inc. lifted its stake in Pfizer Inc. (NYSE:PFE) by 136.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 346,873 shares of the biopharmaceutical company’s stock after purchasing an additional 200,273 shares during the quarter. Pfizer comprises approximately 4.8% of Garland Capital Management Inc.’s holdings, making the stock its 6th largest position. Garland Capital Management Inc.’s holdings in Pfizer were worth $12,730,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently modified their holdings of the company. BlackRock Inc. boosted its position in shares of Pfizer by 0.8% in the 2nd quarter. BlackRock Inc. now owns 427,534,404 shares of the biopharmaceutical company’s stock worth $13,980,372,000 after purchasing an additional 3,464,207 shares in the last quarter. State Street Corp increased its stake in shares of Pfizer by 0.3% in the 1st quarter. State Street Corp now owns 292,621,398 shares of the biopharmaceutical company’s stock worth $9,551,162,000 after purchasing an additional 830,299 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Pfizer by 1.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 57,111,863 shares of the biopharmaceutical company’s stock worth $1,867,559,000 after purchasing an additional 1,024,264 shares in the last quarter. Sanders Capital LLC increased its stake in shares of Pfizer by 5.0% in the 2nd quarter. Sanders Capital LLC now owns 28,282,011 shares of the biopharmaceutical company’s stock worth $1,046,595,000 after purchasing an additional 1,349,012 shares in the last quarter. Finally, Swiss National Bank increased its stake in Pfizer by 1.4% in the 2nd quarter. Swiss National Bank now owns 23,365,691 shares of the biopharmaceutical company’s stock worth $764,058,000 after buying an additional 327,400 shares in the last quarter. 69.08% of the stock is currently owned by hedge funds and other institutional investors.
Shares of NYSE:PFE traded up $0.75 during trading on Friday, reaching $38.18. The company’s stock had a trading volume of 28,992,325 shares, compared to its average volume of 20,809,482. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78. Pfizer Inc. has a 12 month low of $27.88 and a 12 month high of $40.97. The firm’s 50 day simple moving average is $36.59 and its two-hundred day simple moving average is $36.49. The stock has a market capitalization of $212.16 billion, a PE ratio of 15.15, a price-to-earnings-growth ratio of 3.10 and a beta of 0.66.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be issued a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a dividend yield of 3.98%. The ex-dividend date of this dividend is Thursday, November 5th. Pfizer’s payout ratio is 51.53%.
A number of equities research analysts have issued reports on the company. Berenberg Bank assumed coverage on Pfizer in a research note on Tuesday, September 29th. They issued a “hold” rating and a $38.00 price target for the company. Truist initiated coverage on Pfizer in a research report on Friday. They set a “buy” rating and a $42.00 price objective for the company. Mizuho restated a “buy” rating and set a $43.00 price objective on shares of Pfizer in a research report on Tuesday, September 15th. Royal Bank of Canada set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a research report on Friday, October 16th. Finally, Morgan Stanley raised their price objective on Pfizer from $36.00 to $42.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. Pfizer has a consensus rating of “Hold” and an average price target of $39.81.
In other news, Director Ronald E. Blaylock acquired 13,000 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was acquired at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the purchase, the director now directly owns 4,000 shares in the company, valued at $154,200. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.08% of the stock is owned by company insiders.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.
Read More: How Do Front-End Loads Impact an Investment?
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.